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Deconvoluting key biological mechanisms forms the framework for therapeutic discovery. 
Strategies that enable effective translation of those insights along the development and 
regulatory path, ultimately, drive validated clinical application in patients and populations. 
Accordingly, parity in What versus How we transform novel mechanistic insights into 
therapeutic paradigms is essential in achieving success. Aligning molecular discovery with 
innovations in structures and processes along the Discovery-Development-Regulation-
Utilization continuum maximizes the return on public and private investments for next 
generation solutions in managing health and disease. 
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The whole is greater than the sum of its parts. 
Aristotle 
When considering therapeutic innovation, we naturally focus on biological discovery and the 
associated advances in technology, which have revolutionized clinical management paradigms 
and the delivery of care to patients and populations.1 This evolution reflects the exponential 
growth in bio-innovation propelled by public-private partnership investment in generating 
platforms for solutions to health and disease that benefit communities, now and in the future.2 
This scientific revolution drives the development of increasingly precise solutions, leveraging 
insights in molecular mechanisms within a systems context underlying pathophysiology which 
offer biologically-based targets for novel therapies, enhance the ability to find cures, and 
restrict adverse events.3 Indeed, the increasing toolbox of cutting-edge platforms has produced 
unprecedented opportunities to individualize and indeed optimize drugs, devices, and their 
delivery, that can be best aligned across the spectrum of diseases, communities, and 
geographies to reach global populations in need.1 The biotechnology and pharmaceutical 
industry, in turn, has translated these biological advances into new preventive, diagnostic, and 
treatment approaches that are evolving health and the care of patients and their diseases in 
ways that were only imagined a decade earlier.2 The developing framework established by 
biologically targeted biomarker, device, and therapeutic paradigms alters the one-size-fits-all 
method to managing patients into individualized health solutions.4 These developments are 
poised to advance, and that acceleration is reflected in emerging fields like regenerative 
medicine which is poised to drive the management of degenerative diseases and wellness 
through direct manipulation of innate regenerative reserves for tissue and organ renewal.5 
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In every chain of reasoning, the evidence of the last conclusion can be no greater than that of 
the weakest link of the chain, whatever may be the strength of the rest. 
Thomas Reid 
Clearly, this revolution in biology and molecular discovery is the engine of disruptive innovation 
that ultimately propels the development of novel paradigms to maintain health and treat 
disease. However, regardless of the strength of that engine of invention, clinical translation of 
basic innovation can only advance at the rate of the slowest component of the Discovery-
Development-Regulation-Utilization (DDRU) continuum.2 Translation and ultimately adoption 
into the clinic can only be accelerated if we begin to streamline clinical trial processes.6 Greater 
rates of success in clinical development will be achieved by innovation in the development of 
biomarkers that can predict responses, outcomes, and adverse events that advantage novel 
clinical trial designs.7, 8 Regulatory decisions about relative value of developing therapeutics will 
reflect new paradigms in assessing relative risk and benefit.9-11 Increased access to expensive 
biological medicines, whose associated prices are unsustainable for healthcare systems with 
finite resources, will be achieved through novel regulatory pathways encouraging the 
availability of biosimilars.12 Ultimately, innovation in the components of the processes that 
translate novel molecular discoveries into cutting-edge therapies are as important, if not more 
so, than the molecular targets being translated.2 
These considerations are underscored by considering the emerging field of regenerative 
medicine, which is revolutionizing all aspects of therapeutic disease management, with a 
particular focus on degenerative diseases.13 The paradigm suggests that we can improve the 
endogenous regenerative capacities of tissues that undergo disruption because of injury, 
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disease or chronic insult by stimulating tissue-specific regeneration, and/or amplifying 
endogenous repair propensity.14 For example, articular cartilage damage ultimately progresses 
to end-stage osteoarthritis, affecting about a million people in the U.S.15 In that context, 
autologous chondrocyte implantation (ACI) regimens have become standard-of-care in 
specialized orthopedic clinics focused on osteoarthritis.15 Similarly, myocardial damage from 
ischemic heart disease has produced an explosion in chronic heart failure with its associated 
morbidities and mortality. This is another example in which regenerative approaches through 
the provision of stem cells instructed to repair the damaged myocardium and restore cardiac 
function is potentially revolutionizing the management of heart failure.13, 14, 16-18 However, while 
these technological approaches are poised to transform the outcomes of debilitating and 
deadly conditions, their penetration to the management of patients and populations is 
hindered by regulatory structures and regulations which have not kept pace. Indeed, there is 
marked variation in marketing, clinical practice guidelines, local and central regulation, as well 
as reimbursement policies across national jurisdictions.19 In that context, the majority of 
research and development activities in this field are still undertaken locally by academic 
developers and small and medium-sized enterprises.19, 20 These consideration highlight the 
need for improved coordination across medical and regulatory communities.19, 20 Moreover, 
there is a need to build platforms for knowledge sharing, collaboration and learning among 
academia, developers and regulatory authorities.19 New models of pre-competitive 
collaboration should be utilized to increase research efficiencies while collaborations between 
regulatory agencies and interactions with developers need to be strengthened and 
harmonized.19, 20 The importance of these issues can best be appreciated by considering that 
6 
 
the FDA has declared these opportunities for innovation a key priority to advance regenerative 
therapies into patients and populaitons.21 
Similarly, biomarkers have transformed health care management paradigms across a broad 
spectrum of diseases.3 These include biomarkers that forecast who will develop a disease, those 
that prognose whose disease will advance, and those that predict who will respond to therapy.8 
Nowhere is the impact of biomarkers more apparent than in the management of patients with 
cancer.22, 23 In that context, biomarkers can segment the population of patients with a 
particular type of cancer into the precise mutations that underlie their specific disease, 
providing a mechanistic target that, in many cases, is sensitive to an emerging biologically-
directed therapy.24 These biomarker-driven approaches to molecularly segmenting tumors by 
mutational identity is revolutionizing the development of novel biological therapies and the 
associated transformation of clinical trials paradigms to accelerate their approval and 
availability to patients that need them.24, 25 In turn, this acceleration of discovery and 
development is reciprocally driving biomarker innovation, to identify more sensitive and 
specific diagnostic paradigms for predicting therapeutic results and eliminating adverse events 
of novel therapeutics.8, 26 Development of the paradigm for model-informed proarrhythmic risk 
assessment of drugs is an example of innovation in the design of biomarker paradigms that 
minimize the risk of adverse events.27 In addition, the rapid evolution of targeted therapies in 
oncology, many of which are toxic, has entrained the regulatory sciences to match that 
innovation with novel paradigms that quantify the relative benefit and risk of new therapies, to 
enable only compounds with the most favorable therapeutic and safety profiles to be approved 
for patients.11, 26, 28 Beyond the classical biomarkers encompassing cell and molecular analytes, 
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emerging technologies encompassing wearable biosensors with their ability to actuate real time 
reporting of basic pathophysiological metrics are poised to transform the field by monitoring 
the therapeutic and adverse effects of novel agents.11, 26, 28 It is noteworthy that while the pace 
of biomarker development is accelerating, there remain gaps in commercial incentives that 
drive biomarker innovation.29 Moreover the growing dependence of clinical drug development 
programs on biomarkers has created previously unanticipated challenges in ethical frameworks 
surrounding human clinical trials.7 
Bench-to-bedside translation continues to drive innovation across the DDRU continuum. Case in 
point, deconvolution of the contribution of the IL-23/TH17 molecular pathways to 
inflammatory diseases has revealed pathophysiological processes common to a variety of 
autoimmune-mediated conditions.30 Indeed, the recognition of IL-23 and IL-17 as key cytokines 
in promoting inflammation and tissue destruction has led to the development of several 
biologic agents.30 In turn, these mechanistic insights have been translated into unprecedented 
therapeutic achievements for conditions including psoriasis, psoriatic arthritis, and rheumatoid 
arthritis.30 However, it is noteworthy that these agents, in the class of biologics, generally have 
been burdened by high costs which are unsustainable for health care systems with limited 
resources.2 In that context, innovations in the regulatory sciences established the biosimilars 
program of the European Medicines Agency (EMA) and, more recently, the FDA which provide 
pathways for the development of economic generic alternatives once the patent life of 
innovator products has elapsed.12, 31 In turn, these programs maximize opportunities for access 
to those important agents by the broadest populations of the neediest patients.31 
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In the context of the burgeoning opioid crisis, neonatal abstinence syndrome has become a 
major problem for babies born to addicted mothers.32 Buprenorphine has demonstrated an 
efficacy advantage over standard opioid replacement therapy for the neonatal abstinence 
syndrome in both controlled clinical trials and treatment settings.32 Buprenorphine is safe in the 
neonatal abstinence syndrome, and sublingual dosing has been demonstrated to be feasible in 
the neonatal population.33 Indeed the use of sublingual buprenorphine resulted in a reduction 
in the median duration of treatment, median length of stay, and requirement for adjunctive 
therapies compared to oral morphine.33 It is noteworthy that the total number of treated 
patients in these cohorts is modest, although the consistency in effect size in different 
populations provides external validity to the findings.32, 33 However, these types of studies, in 
which cohorts of patients available to individual investigators are modest, can be remarkably 
accelerated in the future by building public-private partnerships across heterologous platforms 
to share data, patients, and approaches through digital technologies.34, 35 
Advances in the development of prevention, detection, and treatment of diseases have 
amplified beyond the limits of our past concepts of canonical small molecule therapeutics, 
reflecting emerging insights into molecular mechanisms and biological targets.2-4 While success 
in discovery innovation has been dramatic, the translation of those laboratory-based inventions 
into effective therapies for individual patients and scalable for populations has been hindered 
by a lag in parallel improvements in supporting structures along the DDRU continuum.2 
Emerging process improvements along this continuum should maximize the impact of discovery 
innovations by facilitating their translation into novel therapeutic paradigms to maintain health, 
and prevent and cure disease. 
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